What You Should Know
- Covera Health and Medmo have officially merged into a single organization, creating a unified platform that manages diagnostic imaging for nearly 6 million Americans.
- The combined entity is backed by additional capital from Insight Partners and serves major clients, including Walmart, Blue Cross Blue Shield of Michigan, and three of the five largest national health plans.
- Covera’s AI-driven platform focus on diagnostic accuracy has produced up to 12 percent lower downstream healthcare costs by routing patients to high-performing Centers of Excellence.
- Medmo’s care coordination technology has facilitated over 1 million patient journeys, delivering a 35 percent reduction in radiology spend and 30 percent higher study completion rates.
- The new infrastructure “closes the loop” in radiology, managing the entire lifecycle from the initial referral and scheduling to the delivery of clinically significant findings.
In the modern healthcare journey, radiology is often the point where critical clinical decisions are made—and where care frequently goes off the rails. A study that is never completed, performed at a sub-par facility, or interpreted with insufficient precision can contaminate every subsequent treatment decision. Covera Health and Medmo have announced their combination to solve this foundational crisis, merging Covera’s expertise in diagnostic quality with Medmo’s high-touch care coordination infrastructure.
Historically, health plans and employers have struggled with the “invisible variation” in imaging quality. The same MRI, ordered for the same clinical reason, can yield vastly different results depending on the facility and the radiologist. By joining forces, Covera and Medmo are creating the first platform that ensures a patient not only reaches the right imaging center but that the resulting report is accurate and actionable for the entire care team.
Solving the “Visibility Gap” from Referral to Results
One of the most persistent hurdles in diagnostic imaging is that providers often lose visibility the moment a patient walks out of the office with a paper order. Medmo was built specifically to close this gap by managing the patient journey through scheduling, prior authorization, and engagement. Operating in all 50 states, the Medmo platform has already demonstrated a 30 percent increase in study completion rates, ensuring that the “missing foundation” of a diagnosis is actually captured.
By integrating Medmo’s coordination engine with Covera’s AI-powered quality oversight, the combined organization now brings clinical intelligence to every step of the imaging process. Covera’s platform measures accuracy across more than 1,100 sites, routing members to “Centers of Excellence” that have been actuarially validated to improve outcomes. This ensure that when a study is finally performed, it serves as a reliable basis for authorized procedures and interventions.
A New Infrastructure for Value-Based Care
For the thousands of value-based primary care physicians now connected to the combined platform, this merger provides a strategic “system of action.” The infrastructure doesn’t just record data; it surfaces clinically significant findings and routes them back to the referring physician in real-time. This level of integration is essential for managing downstream utilization and preventing the unnecessary procedures that often stem from flawed initial reports.
Jeff Horing, Co-Founder and Managing Director at Insight Partners, noted that diagnostic quality is the “missing foundation” of the value-based care movement. The additional capital provided by Insight Partners is intended to accelerate the expansion of this new model, moving it from an incremental improvement to a foundational piece of national healthcare infrastructure. As the organization scales, it aims to continue driving down radiology spend while simultaneously increasing the precision of the U.S. healthcare system.
Why This Matters
For healthcare executives, this represents a move toward “Integrated Diagnostic Management.” As employers and payers face mounting pressure to control costs, the 12 percent reduction in downstream expenses offered by Covera’s platform becomes a powerful lever. This combined entity isn’t just a new vendor; it’s a quality-control layer for the most critical diagnostic tool in the medical arsenal.
